Bench to Bedside OnDemand: The Growing (Anti)body of Evidence for the Treatment of Mild-to-Moderate COVID-19Premiere Date: Wednesday, May 12, 2021
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, May 12, 2022
Note: Credit Is No Longer Available
|Peter Chen, MD (Moderator)
Professor of Medicine and Biomedical Sciences
Director, Division of Pulmonary and Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
|Gregory Huhn, MD, MPHTM
COVID-19 Vaccination Coordinator and Senior Director of HIV Services, Cook County Health
Associate Professor, Department of Internal Medicine, Division of Infectious Disease
Rush University Medical Center
|Margot Savoy, MD, MPH, FAAFP, FABC, CPE, CMQ, FAAPL
Department of Family and Community Medicine
Lewis Katz School of Medicine at Temple University
The novel SARS-CoV-2 virus caused the rapid global spread of COVID-19, and while coronavirus is often mild and self-limiting, approximately 10% of mild SARS-CoV-2 infections progress to severe symptoms, including respiratory distress syndrome, and up to 20% of symptomatic patients develop critical disease with clinical complications including pneumonia and hyper-inflammation. Several repurposed drugs have been used to treat patients hospitalized with serious COVID-19 disease, with monoclonal antibodies (mAbs) being one of the first therapies offered by the FDA. But despite promising results, the demand for treatment for mild-to-moderate COVID-19 has not met expectations, as many health care providers may not be familiar with or aware that preventative treatments are available for mild-to-moderate COVID-19.
This CME Outfitters Live and OnDemand on early intervention treatments following diagnosis of COVID-19 as a way to reduce progression to severe disease will include the latest data on the efficacy and safety of mAb therapies and strategies for addressing knowledge and practice barriers to improve patient access to these therapies.
At the end of this CE activity, participants should be able to:
- Integrate screening assessments for the early and accurate diagnosis of mild-to-moderate COVID-19 to guide treatment decision-making in high-risk patient groups.
- Apply the latest data on the efficacy and safety of monoclonal antibody therapies to treatment decisions for patients with mild-to-moderate COVID-19.
- Implement strategies to address knowledge and practice barriers to patient access to infusion service for monoclonal antibody therapy.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize screening assessments used for the early and accurate diagnosis of mild-to-moderate COVID-19 to guide treatment decision-making in high-risk patient groups.
- Discuss the latest data on the efficacy and safety of monoclonal antibody therapies to treatment decisions for patients with mild-to-moderate COVID-19.
- Describe strategies to address knowledge and practice barriers to patient access to infusion service for monoclonal antibody therapy.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Physicians, PAs, nurse practitioners, nurses, infusion center nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Chen reports that he is on the advisory board for Eli Lilly and Company.
Dr. Huhn reports that he receives grants and research support from Eli Lilly and Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and ViiV Healthcare. He is on the advisory board for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and ViiV Healthcare.
Dr. Savoy has no disclosures to report.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).